​

Roivant Sciences (ROIV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ROIV Stock Forecast

Roivant Sciences (ROIV) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $46.14, with a high of $55.00 and a low of $40.00. This represents a 10.36% increase from the last price of $41.81.

$10 $19 $28 $37 $46 $55 High: $55 Avg: $46.14 Low: $40 Last Closed Price: $41.81

ROIV Stock Rating

Roivant Sciences stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (93.33%), 1 Hold (6.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 15 1 14 0 Strong Sell Sell Hold Buy Strong Buy

ROIV Price Target Upside V Benchmarks

TypeNameUpside
StockRoivant Sciences10.36%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts4521
Avg Price Target$50.00$48.20$34.67
Last Closing Price$41.81$41.81$41.81
Upside/Downside19.59%15.28%-17.08%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26291--12
Aug, 26291--12
Jul, 262101--13
Jun, 262101--13
May, 262101--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 09, 2026Yastin SunejaGuggenheim$46.00$41.4810.90%10.02%
Sep 09, 2026UBS$55.00$41.4832.59%31.55%
Sep 08, 2026H.C. Wainwright$47.00$42.0311.82%12.41%
Sep 08, 2026Jefferies$52.00$41.7024.70%24.37%
Aug 07, 2026Douglas TsaoH.C. Wainwright$41.00$35.1216.74%-1.94%
May 26, 2026Yastin SunejaGuggenheim$36.00$29.9620.16%-13.90%
May 21, 2026Cowen & Co.$41.00$32.1827.41%-1.94%
May 21, 2026David RisingerLeerink Partners$42.00$32.4129.59%0.45%
Apr 16, 2026Piper Sandler$40.00$29.2636.71%-4.33%
Mar 04, 2026Douglas TsaoH.C. Wainwright$34.00$28.8118.01%-18.68%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 09, 2026GuggenheimBuyBuyhold
Sep 09, 2026Cowen & Co.BuyBuyhold
Sep 08, 2026JefferiesBuyBuyhold
Aug 28, 2026H.C. WainwrightBuyBuyhold
Aug 25, 2026Cantor FitzgeraldOverweightOverweighthold
Aug 10, 2026CitigroupBuyBuyhold
Aug 07, 2026H.C. WainwrightBuyBuyhold
Aug 06, 2026Cowen & Co.BuyBuyhold
Jul 31, 2026Bank of America SecuritiesNeutralNeutralhold
May 26, 2026GuggenheimBuyBuyhold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 $4 $5 $6 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-1.42$5.55$-0.24$-0.43---
Avg Forecast$-1.59$5.22$-0.77$-1.09$-1.07$-0.47$0.20
High Forecast$-0.73$5.41$-0.72$-0.81$-0.82$-0.22$0.33
Low Forecast$-2.63$4.98$-0.81$-1.29$-1.39$-0.77$0.09
Surprise %-10.69%6.32%-68.83%-60.55%---

Revenue Forecast

$0 $500M $1B $2B $2B $3B Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$61.28M$32.71M$29.05M$8.26M---
Avg Forecast$52.28M$181.74M$92.10M$34.74M$61.48M$762.32M$1.57B
High Forecast$78.79M$193.36M$139.48M$59.09M$92.67M$1.15B$2.37B
Low Forecast$30.60M$176.37M$56.33M$17.27M$35.98M$446.16M$920.09M
Surprise %17.22%-82.00%-68.45%-76.23%---

Net Income Forecast

$-3B $-1B $300M $2B $3B $5B Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-1.01B$4.35B$-171.98M$-299.77M---
Avg Forecast$-1.32B$4.35B$-605.08M$-804.05M$-911.26M$-387.83M$163.44M
High Forecast$-608.11M$4.50B$-596.22M$-672.44M$-682.96M$-178.73M$271.22M
Low Forecast$-2.19B$4.14B$-670.75M$-1.07B$-1.15B$-643.57M$75.32M
Surprise %-23.53%-0.07%-71.58%-62.72%---

ROIV Forecast FAQ

Is Roivant Sciences stock a buy?

Roivant Sciences stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Roivant Sciences is a favorable investment for most analysts.

What is Roivant Sciences's price target?

Roivant Sciences's price target, set by 15 Wall Street analysts, averages $46.14 over the next 12 months. The price target range spans from $40 at the low end to $55 at the high end, suggesting a potential 10.36% change from the previous closing price of $41.81.

How does Roivant Sciences stock forecast compare to its benchmarks?

Roivant Sciences's stock forecast shows a 10.36% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Roivant Sciences over the past three months?

  • September 2026: 16.67% Strong Buy, 75.00% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 16.67% Strong Buy, 75.00% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 15.38% Strong Buy, 76.92% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.

What is Roivant Sciences’s EPS forecast?

Roivant Sciences's average annual EPS forecast for its fiscal year ending in March 2027 is $-1.07, marking a 148.84% increase from the reported $-0.43 in 2026. Estimates for the following years are $-0.47 in 2028, and $0.2 in 2029.

What is Roivant Sciences’s revenue forecast?

Roivant Sciences's average annual revenue forecast for its fiscal year ending in March 2027 is $61.48M, reflecting a 644.32% increase from the reported $8.26M in 2026. The forecast for 2028 is $762.32M, and $1.57B for 2029.

What is Roivant Sciences’s net income forecast?

Roivant Sciences's net income forecast for the fiscal year ending in March 2027 stands at $-911M, representing an 203.99% increase from the reported $-300M in 2026. Projections indicate $-388M in 2028, and $163.44M in 2029.